

Bioassay Guided Isolation and Docking studies of a Potential β -Lactamase Inhibitor from *Clutia myricoides*

Mahmoud A. Elfaky¹, Ali M. El-Halawany², Abdulrahman E Koshak¹

Khalid Z Alshali³, Moustafa El-Araby⁴ and Hossam M. Abdallah^{1,2,*}

¹Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia

²Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt

³Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

⁴Department of Medicinal Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia

* Correspondence: Dr. Hossam M. Abdallah; email: hmafifi2013@gmail.com, Tel.: +966-544-

733-110




Figure S1: HRESIMS spectrum of compound 2.

Dr.Hossam
Sample : CLMC-6-1 CDCl₃




Figure S2: ¹H NMR spectrum of compound **2** (850 MHz, CDCl₃).





Figure S3: ¹³C NMR spectrum of compound 2 (214 MHz, CDCl₃).






Figure S5: HMBC spectrum of compound **1** (CDCl₃).




Figure S6: HRESIMS spectrum of compound **5**.




Figure S7. ¹H NMR spectrum of compound 5 (850 MHz, CDCl₃).




Figure S8: ¹³C NMR spectrum of compound 5 (214 MHz, CDCl₃).




Figure S9: HSQC spectrum of compound 5 (CDCl₃).




Figure S10: HMBC spectrum of compound 5 (CDCl_3).




Figure S11: NOESY spectrum of compound 5 (CDCl₃).